Serplulimab
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: hetronifly, HLX10
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Serplulimab is a drug catalogued in DrugCentral. It was first approved by the EMA in 2025. DrugCentral lists 1 molecular target, including PDCD1. Recorded indications include Small cell lung cancer.
- Molecular targets: PDCD1 (1 listed in DrugCentral).
- Indications: Small cell lung cancer.
- ATC code: L01FF12 (PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Small cell lung cancer
Mechanism & targets
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Programmed cell death protein 1 | PDCD1 | blocker | Kd 8.62 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2025-02-03 | EMA | — | Accord Healthcare S.L.U. | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L01FF12 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Neutrophil count decreased | 69.5 |
| Myelosuppression | 67.0 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | — |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Serplulimab used for?
DrugCentral lists the following indications for Serplulimab: Small cell lung cancer.
How does Serplulimab work?
Its molecular targets in DrugCentral include PDCD1 (blocker).
When was Serplulimab first approved?
Serplulimab was first approved by the EMA in 2025.
Browse: all drugs starting with S · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5807 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL4594550 — compound record and bioactivity
- FDA UNII S3GQZ2K36V — substance identity
- UniProt Q15116 (PDCD1) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.